According to Precision Business Insights, the Glioblastoma Multiforme Treatment Market research report provides industry size and growth.
According to Precision Business Insights (PBI), the latest report the global food glioblastoma multiforme treatment market is expected to be worth USD x million in 2022 and projected to grow at x% CAGR from 2023 to 2029. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. The global glioblastoma multiforme treatment market is growing at a significant rate due to increase in the geriatric population, and changes in the lifestyle. The increase in alcohol consumption, a rise in malaria prevalence, and the increase in the incidence of seizures are the key factors driving the global glioblastoma multiforme treatment market. In addition to that, increased R & D in gene therapy, molecular biotechnology for the treatment of CNS associated disorders, urgent need of alternative treatment procedures due to the resistance of glioma cells to conventional therapies are anticipated to boost the glioblastoma treatment market. However, major restraints of the glioblastoma multiforme disease market are current treatment therapies such as radiation and chemotherapy does not prevent tumor recurrence that causes death in glioblastoma multiforme patients. Similarly, high expenditure for the genomics-based research, less number of drugs available in the market, and the high cost of treatment are expected to hinder the glioblastoma multiforme treatment market growth. The global Glioblastoma multiforme treatment market is divided into following categories-
Drug Type
Distribution Channel
Request Sample: https://www.precisionbusinessinsights.com/request-sample/?product_id=16248
Hospital, retail and online pharmacies And lastly on the basis of geographical regions, the glioblastoma treatment market segmented into following regions- North America, Asia-Pacific, Europe, the Middle East & Africa, and Latin America. North America dominates the glioblastoma multiforme disease market followed by Europe and Asia-Pacific. North America region growth is attributed to increase in the prevalence of glioblastoma multiforme disease, investments in R &D, and increasing CNS cancers in aging population. Company'™s betting heavily on research activities due to lack of drugs to treat glioblastoma multiforme in the market. Similarly, National Brain Tumor Society, Brain Tumor Foundation of Canada, and American Brain Tumor Association are the health organizations engaged in raising awareness about glioblastoma multiforme leading to the growth of glioblastoma multiforme treatment market. Europe glioblastoma multiforme disease market revenue growth is driven by increase in geriatric population, change in lifestyle and increase in research and development activities by various pharmaceutical companies. Asia-Pacific is expected to be the fastest growing market due to improved healthcare infrastructure, and rising awareness of glioblastoma multiforme treatment.
Some of the key players in global glioblastoma multiforme treatment market are Merck & Co Inc. (U.S.), Teva Pharmaceutical Industries, Ltd. (Israel), Arbor Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Celldex Therapeutics, Inc. (U.S.), Bristol-Myers Squibb Co. (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), Apogenix (Germany), Pfizer, Inc. (U.S.),
CANbridge Life Sciences acquired license for to develop, manufacture and commercialize Apogenix'™s APG101 onco-immunotherapy in glioblastoma for China. Increase in prevalence of brain tumors driving the growth of glioblastoma multiforme treatment market. Moreover, various drugs which are under clinical trials are expected to fuel the growth of glioblastoma multiforme treatment market. Rising product approvals from USFDA also expected to drive revenue of glioblastoma treatment market. For e.g. in 2005, USFDA approved Temozolomide (Temodar) capsules, developed by Schering Corporation (Merck & Co., Inc.) to treat newly diagnosed patients with glioblastoma multiforme disease associated with radiotherapy and then as maintenance treatment. Similarly, entry of generics into the market also increases the growth of glioblastoma multiforme treatment market.